Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapies for b-cell lymphomas comprising administration of Anti-cd20 antibody

a technology of b-cell lymphomas and anti-cd20, which is applied in the field of anti-cd20 antibodies, can solve the problems of often subjected to disease relapse in the treatment of patients, and achieve the effect of improving the over-all response rate and facilitating synergistic

Inactive Publication Date: 2012-10-11
GRILLO LOPEZ ANTONIO J
View PDF0 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The combined therapeutic approaches demonstrate a synergistic effect, significantly increasing the overall response rate, particularly in patients with prior bone marrow or stem cell transplantation, and effectively treating relapsed or refractory B-cell lymphomas, including various types beyond low-grade non-Hodgkin's lymphoma.

Problems solved by technology

However, while anti-CD20 antibodies and, in particular, RITUXAN® (U.S.; in Britain, MABTHERA®; in general Rituximab), have been reported to be effective for treatment of B-cell lymphomas, such as non-Hodgkin's lymphoma, the treated patients are often subject to disease relapse.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009]This invention encompasses combined therapeutic regimens for the treatment of B-cell lymphomas. In general, such methods include a method for treating relapsed B-cell lymphoma, where a patient having prior treatment for lymphoma has relapsed and is administered a therapeutically effective amount of a chimeric anti-CD20 antibody. Such prior treatments can include, for example, previous treatment with anti-CD20 antibodies, treatments which included a bone marrow or stem cell transplantation, radiotherapy and chemotherapy. The previous chemotherapy may be selected from a wide group of chemotherapeutic agents and combination regimens, including CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA with or without subsequent G-CSF treatment), VAD, M & P, C-Weekly, ABCM, MOPP and DHAP.

[0010]Also included in the methods of the invention are methods for treating a subject having B-cell lymphoma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001]This application is a divisional application of U.S. patent application Ser. No. 11 / 840,956, filed Aug. 18, 2007, which is a continuation of U.S. patent application Ser. No. 10 / 196,732, filed Jul. 17, 2002 (abandoned), which is a continuation of U.S. patent application Ser. No. 09 / 372,202, filed Aug. 11, 1999, (now U.S. Pat. No. 6,455,043) which claims priority under 35 U.S.C. Section 119(e) and the benefit of United States Provisional Application Ser. No. 60 / 096,180 filed Aug. 11, 1998, the disclosures of which are incorporated herein by reference in their entireties.FIELD OF THE INVENTION [0002]The invention relates to the use of anti-CD20 antibodies or fragments thereof in the treatment of B-cell lymphomas, particularly the use of such antibodies and fragments in combined therapeutic regimens.BACKGROUND OF THE INVENTION[0003]The use of antibodies to the CD20 antigen as diagnostic and / or therapeutic agents for B-cell lymphoma has previ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P35/00A61K38/00A61K38/21A61K51/00A61K51/10A61P35/04C02F1/00C07K16/00C07K16/28
CPCA61K39/39541A61K51/1027A61K2039/505C02F1/003C02F2307/02A61K39/39558C07K2317/24C07K2317/77C07K16/2887A61K2300/00A61K31/475A61K31/573A61K31/675A61K31/704A61K38/193A61K38/2013A61K38/212A61K38/217A61P35/00A61P35/02A61P35/04A61P37/00A61P43/00A61K39/395C07K16/3061A61K51/1069A61K2039/545C07K2317/56
Inventor GRILLO-LÓPEZ, ANTONIO J.
Owner GRILLO LOPEZ ANTONIO J
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com